Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (b30f2b)
- Development stage
- Unknown
- Lead developer
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation (FMT), developed by the Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal for advanced non-small cell lung cancer (NSCLC), is a live biotherapeutic product administered via oral capsules. The therapy is being investigated in the MORELIA clinical trial (NCT04924374). The active component consists of fecal microbiota sourced from three healthy donors selected for an abundance of bacterial taxa that correlate with a positive response to immunotherapy. The treatment aims to modulate the patient's gut microbiome to enhance the efficacy of concurrent PD-1/PD-L1 checkpoint inhibitor immunotherapy. The trial enrolls patients with stage III/IV NSCLC who are naive to PD-1/PD-L1 inhibitors.
- Other names
- fecal microbiota transplantation-Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal-non-small cell lung cancerMicrobiota Transplant in Advanced Lung Cancer Treated With Immunotherapy
Beyond the preview
Go deeper on fecal microbiota transplantation (b30f2b).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (b30f2b).